Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Yabao Pharma In-licenses China Rights to Cancer Drug from Le Sun Pharma

publication date: Aug 6, 2014
Yabao Pharma partnered with Changzhou Le Sun Pharmaceuticals to co-develop Le Sun's leading molecule, a PLK/PI3K dual inhibitor that is in pre-clinical development for cancer. Yabao acquired exclusive China rights to LS-008 in China while Le Sun Pharma retained most of the exclusive rights in other markets. Founded in 2011, Le Sun Pharma develops oral therapies for cancer. More details....

Stock Symbol: (SHA: 600351)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital